ARQT vs OGN · rev $235.3M vs P/E 3.4, rev $3.02B
Arcutis Biotherapeutics Inc (ARQT) versus Organon & Co (OGN) — a side-by-side from cached financials, not a winner call.
Arcutis Biotherapeutics Inc (ARQT) is a biotechnology company listed on US.
Organon & Co (OGN) is a drug manufacturers - general company listed on US.
Latest reported ARQT revenue for 2026-06-30 was $235.3M. Net income was $3.7M. ARQT currently screens at market cap $1.64B.
Latest reported OGN revenue for 2026-06-30 was $3.02B. Net income was $254.0M. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
ARQT currently screens at market cap $1.64B. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
Not investment advice. Open the ARQT and OGN stock pages for the full models.
Not investment advice.